Clarkston Consulting
Skip to content

Top Life Sciences Insights from 2020

In 2020, life sciences businesses of every shape and size were thrown into a whirlwind of disruption unlike any previous year. As global shutdowns from COVID-19 went into effect, companies in the life sciences industry were rapidly working to support fragile health systems, maintain production, and embrace new styles of work. On top of that, many were rapidly accelerating drug development timelines to create effective treatments against COVID-19. In spite of the challenges, the industry once again demonstrated a steadfast commitment to care and a robust capacity for innovation and transformation. The top life sciences insights from 2020 reflect a balance of the old and new – many strategies and processes are transforming quickly while other foundational elements of the industry are simply evolving and adapting more steadily.

Life Sciences Insights

5 Use Cases for Cost-Cutting Life Sciences Analytics

Life sciences businesses continue to discover new and innovative ways to leverage advanced analytics capabilities to improve their business. Data Scientist and Analytics Lead Maggie Seeds highlights some analytical life sciences insights and some of the ripe opportunities for companies to utilize analytics to drive considerable cost cutting across various business functions.

Learn more on cost cutting analytics with Maggie here

Three Ways to Accelerate Your Path to Commercialization

The move to commercialization has always been one wrought with challenges as it’s a complex orchestration of various moving parts across the scientific, technical, regulatory, and financial aspects of the business. Further complicating matters is the enormous landscape of competitors racing towards the same goal. In this piece, Life Sciences Expert and Director Kevin Hacker explores three ways businesses can accelerate their commercialization journey.

Hear more from Kevin here

Are You Ready to Upgrade Your Quality Management Systems?

A quality management system (QMS) investment is a sizable undertaking with profound impacts to the business well outside the quality function. Many businesses have operated under a particular system for years, creating processes and responsibilities around the system’s functionality and design. Understandably, making the decision to upgrade your QMS is complicated as it can profoundly impact productivity and efficiency. Quality and Regulatory Lead and Associate Partner LaToya Lee provides insight into how businesses can make this decision and what they can hope to gain in the transition.

Read LaToya’s thoughts here

True Patient Engagement: Creating a Single View of the Patient

Developing a comprehensive, effective, and scalable approach to patient engagement is only becoming more difficult. Regulations, new technologies, and new patient expectations have created a challenging atmosphere for engaging each patient effectively. However, the benefits to true patient engagement are well-understood – improved outcomes, better analytics, and improved decision-making are just a few. In this piece, Sales and Marketing Leader Evan Shirley provides life sciences insights in an approach to patient engagement that businesses can follow to enhance their own operations and drive results.

Learn more about patient engagement with Evan here

Simplify the Supply Chain for Your Cell Therapy Products

In this piece, Quality Consultant Susan Shockey discusses a topic that’s top of mind for many life sciences executives – the cell therapy supply chain. The transitions towards cell and gene therapies as thrown supply chain leaders into a flurry of activity as the requirements for these treatments almost completely upheave every aspect of traditional supply chain practices. This piece provides a simple overview of the cell therapy supply chain.

Hear from Susan here

Moving from a LIMS Assessment to a LIMS Deployment

Implementing a new LIMS platform is a significant task – not only due to costs but also constraints on resources. In this journey, most life sciences companies start with a LIMS assessment to understand their needs and identify potential solutions. Making the leap past the assessment can often prove more difficult than it seems. In this piece, Quality and Regulatory Leads LaToya Lee and David Patterson cover life sciences insights into the post-assessment process with recommendations for roadmapping and more.

Learn more from LaToya and David here

Subscribe to Clarkston's Insights

  • I'm interested in...
  • Clarkston Consulting requests your information to share our research and content with you.

    You may unsubscribe from these communications at any time.

  • This field is for validation purposes and should be left unchanged.
Tags: Life Sciences Trends